S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
NASDAQ:PACB

Pacific Biosciences of California (PACB) Stock Forecast, Price & News

$5.84
+0.85 (+17.03%)
(As of 05/13/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.07
$5.94
50-Day Range
$4.67
$11.23
52-Week Range
$4.51
$36.36
Volume
9.75 million shs
Average Volume
7.29 million shs
Market Capitalization
$1.31 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.43
30 days | 90 days | 365 days | Advanced Chart
Receive PACB News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacific Biosciences of California and its competitors with MarketBeat's FREE daily newsletter.

Pacific Biosciences of California logo

About Pacific Biosciences of California

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
Current Symbol
NASDAQ:PACB
CUSIP
69404D10
Employees
728
Year Founded
2004

Sales & Book Value

Annual Sales
$130.51 million
Book Value
$3.27 per share

Profitability

Net Income
$-181.22 million
Net Margins
-130.14%
Pretax Margin
-199.67%

Debt

Price-To-Earnings

Miscellaneous

Free Float
221,242,000
Market Cap
$1.31 billion
Optionable
Optionable

Company Calendar

Last Earnings
5/04/2022
Today
5/15/2022
Next Earnings (Estimated)
8/02/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

2.23 out of 5 stars

Medical Sector

326th out of 1,403 stocks

Analytical Instruments Industry

12th out of 32 stocks

Analyst Opinion: 3.4Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -













Pacific Biosciences of California (NASDAQ:PACB) Frequently Asked Questions

Is Pacific Biosciences of California a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Pacific Biosciences of California stock.
View analyst ratings for Pacific Biosciences of California
or view top-rated stocks.

When is Pacific Biosciences of California's next earnings date?

Pacific Biosciences of California is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Pacific Biosciences of California
.

How were Pacific Biosciences of California's earnings last quarter?

Pacific Biosciences of California, Inc. (NASDAQ:PACB) posted its quarterly earnings data on Wednesday, May, 4th. The biotechnology company reported ($0.37) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by $0.05. The biotechnology company had revenue of $33.17 million for the quarter, compared to the consensus estimate of $32.82 million. Pacific Biosciences of California had a negative net margin of 130.14% and a negative trailing twelve-month return on equity of 36.11%. The business's quarterly revenue was up 14.4% compared to the same quarter last year. During the same quarter last year, the business posted ($0.18) EPS.
View Pacific Biosciences of California's earnings history
.

What price target have analysts set for PACB?

4 equities research analysts have issued 1 year price objectives for Pacific Biosciences of California's stock. Their forecasts range from $6.00 to $41.00. On average, they expect Pacific Biosciences of California's share price to reach $29.20 in the next year. This suggests a possible upside of 400.0% from the stock's current price.
View analysts' price targets for Pacific Biosciences of California
or view top-rated stocks among Wall Street analysts.

Who are Pacific Biosciences of California's key executives?
Pacific Biosciences of California's management team includes the following people:
  • Mr. Christian O. Henry M.B.A., Pres, CEO & Director (Age 54, Pay $1.42M)
  • Ms. Susan G. Kim, Chief Financial Officer (Age 46, Pay $671.49k) (LinkedIn Profile)
  • Mr. Mark Van Oene, Chief Operating Officer (Age 49, Pay $1.12M)
  • Dr. Denis Zaccarin Ph.D., Sr. VP of Product Devel. (Age 56, Pay $510.77k)
  • Mr. Peter J. Fromen, Chief Commercial Officer (Age 47, Pay $1.11M) (LinkedIn Profile)
  • Dr. Stephen Turner, Co-Founder & CTO (Age 54)
  • Ms. Michele Farmer, VP & Chief Accounting Officer (Age 43)
  • Dr. Jonas Korlach Ph.D., Chief Scientific Officer
  • Trevin Rard, Head of Investor Relations
  • Brett Atkins J.D., Ph.D., Gen. Counsel & Corp. Sec.
What is Christian Henry's approval rating as Pacific Biosciences of California's CEO?

2 employees have rated Pacific Biosciences of California CEO Christian Henry on Glassdoor.com. Christian Henry has an approval rating of 100% among Pacific Biosciences of California's employees. This puts Christian Henry in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Pacific Biosciences of California own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacific Biosciences of California investors own include Pfizer (PFE), Gilead Sciences (GILD), Illumina (ILMN), Novavax (NVAX), Advanced Micro Devices (AMD), AT&T (T), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Invitae (NVTA) and Tesla (TSLA).

What is Pacific Biosciences of California's stock symbol?

Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."

Who are Pacific Biosciences of California's major shareholders?

Pacific Biosciences of California's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.89%), BlackRock Inc. (7.40%), Sumitomo Mitsui Trust Holdings Inc. (6.25%), Nikko Asset Management Americas Inc. (6.25%), Bellevue Group AG (2.18%) and Sei Investments Co. (1.75%). Company insiders that own Pacific Biosciences of California stock include Christian O Henry, Eric Schaefer, Kathy Ordonez, Lucy Shapiro, Michael Hunkapiller, Oene Mark Van, Peter Fromen, Susan G Kim and William W Ericson.
View institutional ownership trends for Pacific Biosciences of California
.

Which major investors are selling Pacific Biosciences of California stock?

PACB stock was sold by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, Mirae Asset Global Investments Co. Ltd., Metropolitan Life Insurance Co NY, Sit Investment Associates Inc., Shelton Capital Management, Reynders McVeigh Capital Management LLC, Nan Fung Group Holdings Ltd, and Twin Tree Management LP. Company insiders that have sold Pacific Biosciences of California company stock in the last year include Christian O Henry, Kathy Ordonez, Oene Mark Van, Peter Fromen, Susan G Kim, and William W Ericson.
View insider buying and selling activity for Pacific Biosciences of California
or view top insider-selling stocks.

Which major investors are buying Pacific Biosciences of California stock?

PACB stock was purchased by a variety of institutional investors in the last quarter, including Bellevue Group AG, Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Decheng Capital Management III Cayman LLC, Sei Investments Co., Renaissance Technologies LLC, JPMorgan Chase & Co., and WCM Investment Management LLC.
View insider buying and selling activity for Pacific Biosciences of California
or or view top insider-buying stocks.

How do I buy shares of Pacific Biosciences of California?

Shares of PACB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pacific Biosciences of California's stock price today?

One share of PACB stock can currently be purchased for approximately $5.84.

How much money does Pacific Biosciences of California make?

Pacific Biosciences of California has a market capitalization of $1.31 billion and generates $130.51 million in revenue each year. The biotechnology company earns $-181.22 million in net income (profit) each year or ($0.810010) on an earnings per share basis.

How many employees does Pacific Biosciences of California have?

Pacific Biosciences of California employs 728 workers across the globe.

Does Pacific Biosciences of California have any subsidiaries?

The following companies are subsidiares of Pacific Biosciences of California: Circulomics, Omniome, PacBio Singapore PTE Limited, Pacific Biosciences (Shanghai) Co. Ltd., Pacific Biosciences Canada Limited, Pacific Biosciences Germany GmbH, Pacific Biosciences International LLC, Pacific Biosciences Japan GK, and Pacific Biosciences UK Limited.

When was Pacific Biosciences of California founded?

Pacific Biosciences of California was founded in 2004.

What is Pacific Biosciences of California's official website?

The official website for Pacific Biosciences of California is www.pacb.com.

How can I contact Pacific Biosciences of California?

Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at (650) 521-8000, via email at [email protected], or via fax at 302-636-5454.

This page was last updated on 5/15/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.